[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"acute-coronary-syndrome-acs-undergoing-percutaneous-coronary-intervention-pci\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:acute-coronary-syndrome-acs-undergoing-percutaneous-coronary-intervention-pci":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,40,77,113,142,172],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":4},"100642568","livalozet-versus-high-intensity-statin-in-older-patients-with-coronary-artery-disease-undergoing-percutaneous-coronary-intervention-100642568",false,"NCT07626840","Livalozet Versus High-intensity Statin in Older Patients With Coronary Artery Disease Undergoing Percutaneous Coronary Intervention","Pitavastatin With Ezetimibe Combination Therapy Versus High-intensity Statin in Older Patients With Coronary Artery Disease Undergoing Percutaneous Coronary Intervention","SMARTDECISION2","Inclusion Criteria\n\n* Age 75 years or older\n* Patients diagnosed with stable coronary artery disease or acute coronary syndrome and requiring coronary artery intervention due to coronary artery stenosis\n* Patients with primary hypercholesterolemia and mixed dyslipidemia\n* Patients who understand the risks and benefits of treatment, as well as alternatives, and can voluntarily sign the informed consent form\n\nExclusion Criteria:\n\n* Patients with hypersensitivity or contraindications to statins or ezetimibe\n* Patients with active liver disease or persistently elevated AST or ALT levels exceeding three times the upper limit of normal\n* Patients with a history of organ transplantation (kidney, liver, etc.)\n* Pregnant or lactating women\n* Patients with a life expectancy of less than one year due to non-cardiac disease, or those deemed unable to participate in the study and follow-up (based on the medical judgment of the investigator at each site)","ALL","75 Years",{"count":20,"type":21},5000,"ESTIMATED","INTERVENTIONAL",[24],"NA","Acute myocardial infarction is one of the leading causes of death in elderly patients, and the importance of lipid-lowering therapy as a secondary prevention strategy to reduce cardiovascular events is emphasized. The European Society of Cardiology (ESC) and American Heart Association (AHA) guidelines recommend lowering low-density lipoprotein-cholesterol (LDL-C) below 55 mg\u002FdL or by at least 50% from baseline as a treatment goal and recommend high-intensity statin therapy (Atorvastatin 40-80 mg, Rosuvastatin 20 mg). Statins have been shown to reduce cardiovascular risk in elderly patients as well. However, these patients exhibit a higher rate of statin intolerance due to side effects associated with high-intensity statins, such as myalgia, hepatotoxicity, cognitive decline, and increased risk of diabetes. Consequently, dose reduction or discontinuation is required more frequently compared to younger patients. Therefore, establishing an appropriate lipid-lowering strategy for elderly patients is necessary, considering not only efficacy but also drug tolerability. Consequently, in elderly patients, reducing the statin intensity from the outset and considering combination therapy with drugs having different mechanisms of action, such as ezetimibe, may be warranted. Pitavastatin is classified as a moderate-intensity statin. Previous studies have confirmed that Pitavastatin demonstrates non-inferior efficacy compared to Rosuvastatin and Atorvastatin. Several observational studies report that Pitavastatin has fewer drug interactions than other statins and lower rates of diabetes onset and elevated liver enzymes. Therefore, Pitavastatin may be an appropriate choice for moderate-intensity statin therapy in elderly patients. Thus, this study aims to evaluate whether combination therapy with Pitavastatin and Ezetimibe (Livalozet 4\u002F10mg) after coronary intervention in patients aged 75 years or older with coronary artery disease is non-inferior to high-intensity statin therapy (Atorvastatin 40-80 mg or Rosuvastatin 20 mg). If this study demonstrates that moderate-intensity statin therapy combined with ezetimibe is non-inferior to high-intensity statin therapy while also having fewer adverse effects, it could provide evidence for an effective and safe cholesterol treatment option for elderly patients.",[27],"Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)","NOT_YET_RECRUITING","2026-06-08",{"date":31,"type":32},"2026-06-10","ACTUAL",{"date":34,"type":21},"2026-06-01",{"date":36,"type":21},"2031-12-31",{"name":38,"class":39},"Samsung Medical Center","OTHER",{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":17,"minAge":48,"maxAge":4,"enrollmentInfo":49,"targetDuration":51,"studyType":52,"phases":4,"briefSummary":53,"conditions":54,"keywords":56,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":76},"100586058","artificial-intelligence-based-timing-infarct-size-and-outcomes-in-acute-coronary-occlusion-myocardial-infarction-100586058","NCT06910436","Artificial Intelligence Based Timing, Infarct Size and Outcomes in Acute Coronary Occlusion Myocardial Infarction","Artificial Intelligence Based Timing, Infarct Size and Outcomes in Acute Coronary Occlusion Myocardial Infarction Without ST Elevation","ANOMI","Inclusion Criteria:\n\n* Age \\> 18 yrs\n* Working diagnosis of Non- ST Elevation Acute Coronary Syndrome after the assessment by specialist\n\nExclusion Criteria:\n\n* ST-Elevation Myocardial infarction\n* Age \\\u003C 18 yrs\n* Major sustained ventricular arrhythmias\n* Corrupted ECG images\n* Poor digitalisation quality of the ECG","18 Years",{"count":50,"type":21},1500,"12 Months","OBSERVATIONAL","The present study is practice-driven and merely observational and prospective. In clinical routine, patients who suffer from suspected ACS and do not show ST elevation in the ECG, different timing proposals in the guidelines and logistically driven differences lead to considerably variable timings in invasive coronary anatomy assessments. This handling may lead to larger infarct sizes when OMI is overseen. Therefore, the present study aims to observe a) whether an AI model is capable of correctly identify OMI in eligible patients and b) if in these patients troponin peak levels vary depending on the elapsed time between OMI diagnosis and coronary intervention.\n\nAs the model has not been established yet clinically and in the guidelines, it is safe to assume the usual pathway from first medical contact to specialist's attention is undertaken. When a patient presents in an emergency department or places an emergency call, the physicians assess the situation as usal and as stated in the current guidelines1.\n\nIf no STEMI is confirmed, the NSTE-ACS protocol is started. The patients who are ruled out for ACS are excluded from the final analysis (screening). In this case, the AI model is tested on their ECG in order to assess whether there are false positives.\n\nThe patients which are in the ACS \"rule-in\" trail and undergo final coronary angiography will naturally be divided in patients which were classified as OMI and as non-OMI by the AI model. Furthermore, they will present a different \"Time from OMI diagnosis to PCI) and variable troponin peak levels.\n\nBy leveraging this natural variability, a practical distinction and multiple analyses can be done:\n\n1. The feasibility of AI-powered ECG interpretation in the care of patients with suspected ACS and without clear ST-elevation infarction\n2. The accuracy of AI-powered ECG interpretation in detecting OMI compared to the classical STEMI criteria\n3. How infarct size correlates with different ECG readings by AI and (hypothesis generating) if changing the clinical practice could lead to a benefit in patients with suspected OMI.",[55,27],"Coronary Arterial Disease (CAD)",[57,58,59,60,61,62,63,64,65],"Artificial Intelligence","ECG","AI","NSTE-ACS","ACS","Acute Coronary Syndrome","Reperfusion times","PCI","Percutaneous Coronary Intervention","RECRUITING","2026-05-21",{"date":69,"type":32},"2026-05-26",{"date":71,"type":32},"2024-04-01",{"date":73,"type":21},"2026-07-31",{"name":75,"class":39},"Azienda Ospedaliera di Bolzano",1,{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":17,"minAge":48,"maxAge":4,"enrollmentInfo":85,"targetDuration":87,"studyType":52,"phases":4,"briefSummary":88,"conditions":89,"keywords":94,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":76},"100626499","drug-coated-balloon-primary-pci-in-st-segment-elevation-myocardial-infarction-100626499","NCT07436429","Drug-Coated Balloon Primary PCI in ST-Segment Elevation Myocardial Infarction","Drug Coated Balloon-Based Primary PCI in ST-segment Elevation Myocardial Infarction - The DCB-STEMI Multicenter Registry","DCB-STEMI","Inclusion Criteria:\n\n* All ST-elevation MI undergoing Primary PCI\n\nExclusion Criteria:\n\n* In-stent culprit lesion\n* Contraindications to antiplatelets\n* Stent implantation within 3 months before enrollment\n* Cardiac arrest, intubation, or cardiogenic shock\n* Life-expectancy less than one year",{"count":86,"type":21},300,"30 Days","Drug-eluting stent (DES)-based primary percutaneous intervention (pPCI) has been established as the standard of care for patients presenting with ST-segment elevation myocardial infarction (STEMI), having demonstrated superiority over thrombolysis, plain balloon angioplasty, and bare-metal stents. Recently, the use of drug-coated balloons (DCB) has expanded dramatically across a variety of anatomical and clinical settings, including de novo coronary lesions. A DCB-based pPCI strategy may simplify the procedure and mitigate the risks of inadequate stent sizing due to spasm or large thrombus burden, acute stent thrombosis, distal embolization, no reflow, and the relatively higher incidence of late stent-related adverse events compared with elective PCI. Despite these theoretical advantages, data on the safety and efficacy of DCB-based pPCI in STEMI remains limited.\n\nThe aim of this registry is to explore procedural and clinical outcomes of patients with STEMI treated with a DCB-based pPCI strategy.",[90,91,92,93,27],"Myocardial Infarction (MI)","ST-Elevation Myocardial Infarction","STEMI","STEMI (STE-ACS)",[95,96,97,98,99,100,101,102,103],"Drug-coated balloon","Primary percutaneous coronary intervention","De novo coronary lesion","Limus-coated balloon","Paclitaxel-coated balloon","Net adverse clinical events","Bleeding Academic Research Consortium bleeding","ST-segment elevation myocardial infarction","Drug-Eluting Balloon","2026-02-22",{"date":106,"type":32},"2026-02-27",{"date":108,"type":32},"2026-02-08",{"date":110,"type":21},"2026-07-01",{"name":112,"class":39},"Medical University of Vienna",{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":119,"eligibilityCriteria":120,"healthyVolunteers":11,"sex":17,"minAge":48,"maxAge":4,"enrollmentInfo":121,"targetDuration":4,"studyType":22,"phases":123,"briefSummary":124,"conditions":125,"keywords":128,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":137,"completionDateStruct":138,"leadSponsor":140,"locationsCount":76},"100625580","educational-video-to-improve-understanding-and-reduce-anxiety-in-heart-attack-patients-100625580","NCT07424482","Educational Video to Improve Understanding and Reduce Anxiety in Heart Attack Patients","Video-Based Information to Improve Understanding and Reduce Anxiety in Patients With Acute Coronary Syndrome","VID-ACS","Inclusion Criteria:\n\n* first-time Acute Coronary Syndrome\n* Diagnosis of Acute Coronary Syndrome\n\nExclusion Criteria:\n\n* Prior heart catheterization or coronary angiography\n* Severe neurocognitive impairment that precludes valid participation in the study or informed consent",{"count":122,"type":21},140,[24],"Patients who are diagnosed with a heart attack are often confronted with an unexpected hospital admission and an urgent heart catheterization. In this stressful situation, anxiety is common and understanding of the procedure may be limited, even after standard verbal and written explanations.\n\nThis study investigates whether a short educational video, shown in addition to standard medical information, can help patients better understand the heart catheterization procedure and reduce anxiety before the intervention. Patients will be randomly assigned to receive either standard information alone or standard information plus the educational video.\n\nThe study will assess patients' understanding of the procedure, their level of anxiety, and their satisfaction with the information provided. The results may help improve patient education and support in acute cardiac care settings.",[27,126,127],"Anxiety","Patient Education Materials",[126,62,129,130,131,132,133],"Patient Education","Educational Video","Informed Consent","Patient Satisfaction","Coronary Angiography","2026-02-20",{"date":136,"type":32},"2026-02-23",{"date":110,"type":21},{"date":139,"type":21},"2028-04-01",{"name":141,"class":39},"Tobias Schreiber",{"id":143,"slug":144,"hasResults":11,"nctId":145,"briefTitle":146,"officialTitle":147,"acronym":148,"eligibilityCriteria":149,"healthyVolunteers":11,"sex":17,"minAge":150,"maxAge":4,"enrollmentInfo":151,"targetDuration":4,"studyType":22,"phases":153,"briefSummary":155,"conditions":156,"keywords":158,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":167,"completionDateStruct":169,"leadSponsor":171,"locationsCount":76},"100574781","phase-4-genotype-guided-abbreviated-dapt-versus-un-guided-de-escalation-therapy-in-patients-with-acs-and-hbr-100574781","NCT06763744","Genotype-Guided Abbreviated DAPT Versus Un-Guided De-escalation Therapy in Patients With ACS and HBR","SMart Angioplasty Research Team- Genotype-Guided Abbreviated DUal AntIplatelet Therapy Versus Un-Guided De-escalation Therapy in Patients With Acute Coronary SyndromE and High Bleeding Risk (SMART-GUIDE-HBR)","GUIDE-HBR","Inclusion Criteria:\n\n* Patients must be at least 19 years of age\n* Patients who is able to understand risks, benefits and treatment alternatives and sign informed consent voluntarily.\n* Patients presenting with ACS (ST-elevation myocardial infarction \\[STEMI\\] or non-ST-elevation \\[NSTE\\] ACS).\n* Patients with at least one lesion with equal or greater than 50% diameter stenosis requiring treatment with drug-eluting stents in native coronary artery or graft.\n* Patients with high bleeding risk (by ARC-HBR definition or PRECISE-DAPT score 25 or more)\n\nExclusion Criteria:\n\n* Patients unable to provide consent.\n* Patients who need chronic anti-coagulation therapy.\n* Patients suffering from cardiogenic shock or cardiac arrest\n* Patients with known intolerance to aspirin, all P2Y12 inhibitors, or components of drug-eluting stents.\n* Clinically significant out of range values for platelet count (\\\u003C 50,000\u002Fmm3) or hemoglobin (\\\u003C8 g\u002FdL) at screening\n* Non-cardiac co-morbid conditions are present with life expectancy \\\u003C1 year or that may result in protocol non-compliance (per site investigator's medical judgment).\n* Pregnant or lactating women.","19 Years",{"count":152,"type":21},3000,[154],"PHASE4","The aim of this study is to assess the safety and efficacy of the CYP2C19 genotype-guided abbreviated dual antiplatelet therapy (DAPT) strategy versus the un-guided stepwise intensity de-escalation of DAPT strategy in patients with acute coronary syndrome (ACS) and high bleeding risk (HBR) undergoing percutaneous coronary intervention (PCI).",[27,157],"High Bleeding Risk",[159,160,161,162,163],"CYP2C19 Genotype","Acute coronary syndrome","De-escalation therapy","P2Y12 inhibitor monotherapy","High bleeding risk","2025-05-14",{"date":166,"type":32},"2025-05-18",{"date":168,"type":21},"2025-06-01",{"date":170,"type":21},"2029-12-31",{"name":38,"class":39},{"id":173,"slug":174,"hasResults":11,"nctId":175,"briefTitle":176,"officialTitle":177,"acronym":4,"eligibilityCriteria":178,"healthyVolunteers":11,"sex":17,"minAge":48,"maxAge":179,"enrollmentInfo":180,"targetDuration":4,"studyType":22,"phases":182,"briefSummary":184,"conditions":185,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":187,"startDateStruct":189,"completionDateStruct":191,"leadSponsor":193,"locationsCount":76},"100560467","phase-3-efficacy-and-safety-study-of-vicagrel-in-patients-with-acute-coronary-syndrome-acs-undergoing-percutaneous-coronary-intervention-pci-100560467","NCT06577519","Efficacy and Safety Study of Vicagrel in Patients With Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)","Efficacy and Safety of Vicagrel in Patients With With Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI): a Multi-center, Randomized, Double-blind, Double-dummy , Parallel-controlled, Phase III Trial","Inclusion Criteria:\n\n* Patients between 18 and 80 years old, with no gender restrictions.\n* Patients diagnosed with ACS and scheduled for PCI, including STEMI and NSTE-ACS (UA\u002FNSTEMI).\n* Voluntarily sign the ICF and be able to follow the visit arrangements specified in the protocol during the trial period.\n\nExclusion Criteria:\n\n* Expected survival time\\\u003C12 months;\n* Severe liver dysfunction (non heart disease induced ALT or AST\\>3x ULN) and cirrhosis;\n* Pregnant or lactating women, or participants and their partners who plan to become pregnant during the trial period;\n* The researchers determined that other reasons were not suitable for participants in this experiment.","80 Years",{"count":181,"type":21},1000,[183],"PHASE3","This is a multi-center, randomized, double-blind, double-dummy, parallel-controled, phase III trial, aiming to evaluate the effectiveness and safety of long-term continuous administration of Vicagrel capsules in ACS patients undergoing PCI.",[27],"2024-09-28",{"date":188,"type":32},"2024-10-01",{"date":190,"type":32},"2024-09-06",{"date":192,"type":21},"2026-12-30",{"name":194,"class":195},"Jiangsu vcare pharmaceutical technology co., LTD","INDUSTRY"]